A coalition of pharmaceutical companies has formed the Biosimilars Forum, a nonprofit seeking to expand patient access to biosimilars in the United States.
Naloxone is a lifesaving antidote for reversing opioid overdose symptoms and the pharmacist’s role has quickly expanded in managing this population.
At the end of April, FDA approved a new biologic to help prevent and control bleeding in patients with hemophilia B who are 12 years and older. It also is approved for use in perioperative management in this patient population.
The National Association of Boards of Pharmacy (NABP) recently issued a report listing illegal online drug sellers and detailing the threat they pose to the public.
The FDA issued three final guidance documents on biosimilars for pharmaceutical manufacturers and others in late April.